- Oops!Something went wrong.Please try again later.
COPENHAGEN, Denmark and BOSTON, June 20, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (CPH:BIOPOR) (BioPorto) today announced the appointment of Dr. Prasad Devarajan, MD FAAP FASN, as Senior Medical Director effective July 1, 2022.
Dr. Devarajan is considered a world leading Pediatric Nephrologist and physician-scientist and a pioneer in understanding the relationship between Neutrophil gelatinase-associated lipocalin (NGAL) and Acute Kidney Injury (AKI). Dr. Devarajan is Professor of Pediatrics & Developmental Biology, Director of Nephrology and Hypertension, and CEO of the Dialysis Unit at Cincinnati Children’s Hospital Medical Center (Ohio, USA). He is the author of much of the most frequently cited peer-reviewed literature on the topics of kidney disease, nephrology, and renal disease. Dr. Devarajan will share his time between his directorships at Cincinnati Children’s and his executive role at BioPorto.
“I am extremely excited and proud to have a world-renowned nephrologist and NGAL expert join BioPorto as Senior Medical Director,” said Tony Pare, BioPorto’s Chief Executive Officer. “Dr. Devarajan’s unparalleled reputation, knowledge, and expertise will be a tremendous gain for BioPorto as we expand the global market’s understanding of the benefits of The NGAL Test and prepare its submission for FDA review and approval.”
“I have been working with BioPorto for many years and am truly impressed with The NGAL Test and its unique potential to save lives. I believe that access to The NGAL Test as a kidney injury assessment tool will be a major milestone for kidney disease patients and physicians,” said Dr. Devarajan. “I am confident The NGAL Test will redefine the diagnosis of AKI going forward. From a physician’s and scientist’s point-of-view, it will be a privilege to help expand applications and indications for NGAL assays while also evaluating new areas of growth for BioPorto in the field of kidney health. I also look forward to further educating the medical and scientific community on The NGAL Test and ultimately assisting in developing and bringing tests to the market that improve patient outcomes.”
In addition to his appointments at Cincinnati Children’s, Dr. Devarajan serves on the editorial and review boards of more than 20 journals and on multiple US National Institutes of Health (NIH) study sections. He has authored more than 320 peer-reviewed journal articles, and his work has been continuously funded by NIH and several other foundations for over thirty years.
For further information, please contact:
Tim Eriksen, EU Investor Relations, Zenith Advisory, +45 4529 0000, email@example.com
Ashley Robinson, US Investor Relations, LifeSci Advisors, +1 617 430 7577, firstname.lastname@example.org
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.
The Company’s flagship product is The NGAL Test, which has been designed to aid in the risk assessment of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality if not identified and treated early. With the aid of The NGAL Test, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The NGAL Test is CE marked and registered in a number of countries worldwide.
BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com.
Certain statements in this news release are not historical facts and may be forward-looking statements. Forward-looking statements include statements regarding the intent, belief or current expectations with respect to the Company’s expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts, including with respect to the potential FDA clearance, commercialization of The NGAL Test, and the development of future products and new indications. These forward-looking statements, which may use words such as “aim”, “anticipate”, “believe”, “intend”, “estimate”, “expect” and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, and uncertainties that could cause the actual results of operations, financial condition, liquidity, dividend policy and the development of the industry in which the Company’s business operates to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Factors that may impact BioPorto’s success are more fully disclosed in BioPorto’s periodic financial filings with the Danish Financial Supervisory Authority, particularly under the heading “Risk Factors”.